Sudo Biosciences

We are very happy to welcome a new addition to the Sudo Biosciences Medical Team!? Peadar O'Donohoe has recently joined us as Neurology Clinical Development Lead.?? Peadar's knowledge and experience will be a great asset to us and will further support Sudo’s mission in designing and developing novel medicines to transform patients’ lives!??We're excited to have him on our team, and we know he will do great things here! ? Please help us welcome Peadar to the Sudo Team!

We are very pleased to welcome a new member to the Sudo Biosciences Medical Team!??Terrie Walker-Smith?has recently joined us as Study Manager.??? ? Her deep knowledge and expertise in clinical trial management will further support Sudo’s mission in designing and developing novel medicines to transform patients’ lives! ? Please help us welcome?Terrie?to the Sudo Team!

We are very pleased to announce another important addition to the Sudo Biosciences Team!?Waylon Parham has joined as our VP-Finance.?Waylon brings many years of deep financial experience through his leadership roles in both private and public companies.????? ? We look forward to working with him and continuing the important work we are doing at Sudo?to impact patients' lives!?Please join us in welcoming Waylon to the team!???

We are excited to announce a few new members of the Sudo Biosciences Non-Clinical Team!?? ? Mark Evans?has recently joined us as Associate Director of Neuropharmacology;?Alessio Alfieri?is our new Associate Director of Neurodegeneration; and?Roy Gray?joins us as VP, Head of Non-Clinical Development.?? ? Their incredible experience and expertise will further support Sudo’s mission in designing and developing novel medicines to transform patients’ lives! ? Please help us welcome Mark, Alessio and Roy to the Sudo Team!

We are excited to announce two new additions to the Sudo Biosciences Medical Team!??Vassilios Aslanis?recently joined us as VP, Head of Clinical Pharmacology and?Karen Jourdan-Brown?is our new VP, Head of Regulatory Affairs. ? We are so excited to be expanding our team with such top talent, and we look forward to continuing the important work we are doing designing and developing novel medicines to transform patients' lives.?? ? Please help us welcome Vassili?and Karen to Sudo Biosciences!

We are pleased to announce expanded responsibilities for Imran B. and Kejal Patel. In addition to his current role as Chief Business Officer (CBO), Imran has also recently been appointed Chief Financial Officer (CFO). ?We are also happy to share that Kejal has accepted the position of VP, Head of Clinical Operations. Please help us wish them continued success in their new roles.?We are grateful for the passion and excellence they bring to Sudo Biosciences each and every day!

Sudo Biosciences lands additional $30m for TYK2 inhibitors with potential in Alzheimer’s Dementia Discovery Fund (DDF) joins new investors, citing Sudo’s potential in multiple neuroinflammatory diseases, including Alzheimer’s. #longevity #investment #Alzheimers

Improving care for patients living with debilitating neuroinflammatory and autoimmune conditions. ???? We're thrilled to announce our investment in Sudo Biosciences. The company is developing best-in-class precision TYK2 inhibitors, potential game-changers in treating immune-mediated #inflammatory conditions and #neurodegenerative diseases. This investment will support Sudo Biosciences in advancing two precision TYK2 inhibitors into the clinic for neuroinflammatory and autoimmune conditions including #multiplesclerosis, #ALS, and #psoriasis. Read more: https://bwnews.pr/498nmea

Excited to announce we have completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF) (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises the innovation, commercialization and venture capital arm of UPMC. This brings the total raised in this upsized round to $147 million. “We are pleased to welcome these new investors as they each offer unique strategic value which will be meaningful for Sudo as we advance our precision TYK2 inhibitors into the clinic,” said Scott Byrd, Chief Executive Officer, Sudo Biosciences. “This further funding enhances our ability to optimize the development of our pipeline programs.” Read the release: https://lnkd.in/ed_5677K

We had an excellent crowd on hand to hear our very own Mike Bolinder, Scott Byrd, CEO of Sudo Biosciences, and Derek A Small, founder of Luson Bioventures, speaking at the #JP2024 in San Francisco. Special thanks to the Indiana Economic Development Corporation, Elevate Ventures, and Barnes & Thornburg LLP for partnering with BioCrossroads and giving us this incredible opportunity to showcase Indiana as a #lifesciences powerhouse.